Biodistribution of radiolabeled adenosylcobalamin in patients diagnosed with various malignancies.
OBJECTIVE
To study the biodistribution of a vitamin B12 analog, indium In 111-labeled diethylenetriaminepentaacetate adenosylcobalamin (In 111 DAC), in patients recently diagnosed as having primary or recurrent malignancy.


METHODS
Thirty patients (14 women and 16 men) with radiographically or clinically diagnosed breast, lung, colon, sarcomatous, thyroid, or central nervous system malignancies were studied prior to definitive surgery or biopsy. A maximum of 650 microCi (2.2 microg) of In 111 DAC was administered intravenously. Vitamin B12 and folate levels were determined prior to injection. Serum clearance and urinary and stool excretion of the tracer were measured. Images were routinely obtained at 0.5, 3 to 5, and 20 to 24 hours after injection. Biodistribution of In 111 DAC was determined by computer analysis of regions of interest.


RESULTS
Serum T1/2 clearance was 7 minutes. Average urinary and stool excretion of the injected dose over 24 hours was 26.1% and 0.4%, respectively. The greatest focal uptake of In 111 DAC occurred in the liver and spleen, followed by the nasal cavity and salivary and lacrimal glands. The average tumor uptake of the injected dose was 2% at 30 minutes and 1.5% at 24 hours. High-grade primary and metastatic breast, lung, colon, thyroid, and sarcomatous malignancies were all imaged at 3 to 5 hours after injection. Central nervous system tumors and advanced metastatic prostate cancer were best identified at 24 hours. Mammographically occult, palpable, and nonpalpable breast cancers were delineated by In 111 DAC. Low-grade malignancies as well as early skeletal metastatic disease were not effectively imaged by the vitamin B12 tracer. Patients with elevated baseline vitamin B12 or those concurrently taking corticosteroids appeared to have optimal visualization of their malignancies.


CONCLUSIONS
Vitamin B12 may be a useful vehicle for delivering diagnostic and therapeutic agents to various malignancies. Further evaluation of cobalamin analogs and their interaction with transport proteins and cellular receptors within malignant tissue and infection is warranted.
Collins
D A
DA
Section of Nuclear Medicine, Mayo Clinic, Rochester, Minn 55905, USA.
Hogenkamp
H P
HP
O'Connor
M K
MK
Naylor
S
S
Benson
L M
LM
Hardyman
T J
TJ
Thorson
L M
LM
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001943:Breast Neoplasms / Q000378:metabolism; D016543:Central Nervous System Neoplasms / Q000378:metabolism; D003038:Cobamides / Q000008:administration & dosage / Q000097:blood / Q000378:metabolism* / Q000652:urine; D003110:Colonic Neoplasms / Q000378:metabolism; D005260:Female; D006801:Humans; D007205:Indium Radioisotopes / Q000008:administration & dosage / Q000097:blood / Q000378:metabolism* / Q000652:urine; D007262:Infusions, Intravenous; D008175:Lung Neoplasms / Q000378:metabolism; D008297:Male; D008875:Middle Aged; D009369:Neoplasms / Q000097:blood / Q000378:metabolism* / Q000652:urine; D011471:Prostatic Neoplasms / Q000378:metabolism; D012509:Sarcoma / Q000378:metabolism; D013964:Thyroid Neoplasms / Q000378:metabolism; D014018:Tissue Distribution
D003038:Cobamides; D007205:Indium Radioisotopes; C000913:cobamamide